Inventor · disambiguated record
Tobias Raum
Also filed as: RAUM TOBIAS
60 granted patents·40 pending applications·1,001 citations·filing 1998–2025
99Inventor score
Top patents by PatentIndex Score
100 records- 0198US9340621B2Binding molecules for BCMA and CD3AMGEN RES MUNICH GMBH·Filed 2012·Granted May 17, 2016·91 cites·15 claims
- 0297US10294300B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted May 21, 2019·37 cites·16 claims
- 0397US9150664B2Binding molecules for BCMA and CD3AMGEN RES MUNICH GMBH·Filed 2012·Granted Oct 6, 2015·64 cites·15 claims
- 0496US11591396B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2020·Granted Feb 28, 2023·5 cites·33 claims
- 0595US11472886B2Cross-species-specific PSMAxCD3 bispecific single chain antibodyAMGEN RES MUNICH GMBH·Filed 2021·Granted Oct 18, 2022·3 cites·13 claims
- 0695US10301391B2BCMA and CD3 bispecific T cell engaging antibody constructsAMGEN RES MUNICH GMBH·Filed 2017·Granted May 28, 2019·28 cites·19 claims
- 0795US8236308B2Composition comprising cross-species-specific antibodies and uses thereofKISCHEL ROMAN·Filed 2006·Granted Aug 7, 2012·238 cites·9 claims
- 0894US9765157B2Antibody constructs for CDH19 and CD3AMGEN INC·Filed 2015·Granted Sep 19, 2017·13 cites·14 claims
- 0994US9598500B2Binding molecules for BCMA and CD3AMGEN RES MUNICH GMBH·Filed 2012·Granted Mar 21, 2017·22 cites·15 claims
- 1094US7632925B2Antibodies that bind human 17-A1/EpCAM tumor antigenMICROMET AG·Filed 2007·Granted Dec 15, 2009·17 cites·10 claims
- 1193US10683351B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2019·Granted Jun 16, 2020·4 cites·24 claims
- 1293US10519241B2Antibody constructs for EGFRVIII and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted Dec 31, 2019·16 cites·22 claims
- 1392US10781264B2PSMA and CD3 bispecific T cell engaging antibody constructsAMGEN RES MUNICH GMBH·Filed 2017·Granted Sep 22, 2020·8 cites·22 claims
- 1492US10766969B2Binding molecules for BCMA and CD3AMGEN RES MUNICH GMBH·Filed 2012·Granted Sep 8, 2020·8 cites·29 claims
- 1592US9982063B2Pharmaceutical compositions with resistance to soluble CEAAMGEN RES MUNICH GMBH·Filed 2016·Granted May 29, 2018·14 cites·25 claims
- 1692US8784821B1Human-anti-human cd3 binding moleculesKUFER PETER·Filed 2004·Granted Jul 22, 2014·63 cites·23 claims
- 1792US8017748B2Antibody neutralizers of human granulocyte macrophage colony stimulating factorMICROMET AG·Filed 2006·Granted Sep 13, 2011·56 cites·20 claims
- 1892US7919089B2Pharmaceutical composition comprising a bispecific antibody for EpCAMMICROMET AG·Filed 2004·Granted Apr 5, 2011·57 cites·3 claims
- 1991US11692031B2Antibody constructs for CLDN18.2 and CD3AMGEN RES MUNICH GMBH·Filed 2019·Granted Jul 4, 2023·6 cites·18 claims
- 2091US11434302B2Bispecific T cell engaging antibody constructsAMGEN RES MUNICH GMBH·Filed 2017·Granted Sep 6, 2022·7 cites·19 claims
- 2190US12281176B2Binding molecules for BCMA and CD3AMGEN INC·Filed 2021·Granted Apr 22, 2025·1 cites·7 claims
- 2290US10752694B2Binding molecules for BCMA and CD3AMGEN RES MUNICH GMBH·Filed 2014·Granted Aug 25, 2020·11 cites·15 claims
- 2390US9587036B2Cross-species-specific PSMAxCD3 bispecific single chain antibodyKUFER PETER·Filed 2011·Granted Mar 7, 2017·24 cites·34 claims
- 2488US11987633B2Cross-species-specific single domain bispecific single chain antibodyAMGEN RES MUNICH GMBH·Filed 2021·Granted May 21, 2024·1 cites·27 claims
- 2587US11661462B2Optimized cross-species specific bispecific single chain antibody contructsAMGEN RES MUNICH GMBH·Filed 2015·Granted May 30, 2023·4 cites·12 claims
- 2687US10059766B2Antibody constructs for CDH19 and CD3AMGEN RES MUNICH GMBH·Filed 2014·Granted Aug 28, 2018·9 cites·17 claims
- 2787US8394926B2Pharmaceutical compositions with resistance to soluble CEALUTTERBUESE RALF·Filed 2006·Granted Mar 12, 2013·21 cites·34 claims
- 2886US11447567B2Antibody constructs for FLT3 and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted Sep 20, 2022·4 cites·18 claims
- 2986US11155629B2Method for treating glioblastoma or glioma with antibody constructs for EGFRVIII and CD3AMGEN RES MUNICH GMBH·Filed 2019·Granted Oct 26, 2021·2 cites·20 claims
- 3086US8790645B2Pharmaceutical composition comprising a bispecific antibody for EpCAMKUFER PETER·Filed 2011·Granted Jul 29, 2014·10 cites·13 claims
- 3186US8518403B2Expression-enhanced polypeptidesHOFFMANN PATRICK·Filed 2005·Granted Aug 27, 2013·24 cites·22 claims
- 3285US10981998B2Cross-species-specific single domain bispecific single chain antibodyKUFER PETER·Filed 2009·Granted Apr 20, 2021·5 cites·18 claims
- 3384US12435139B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2022·Granted Oct 7, 2025·0 cites·12 claims
- 3484US11352433B2BCMA and CD3 bispecific T cell engaging antibody constructsAMGEN RES MUNICH GMBH·Filed 2019·Granted Jun 7, 2022·2 cites·23 claims
- 3583US2025064927A1Compositions comprising cross-species-specific antibodies and uses thereofAMGEN RES MUNICH GMBH·Filed 2024·Application pending·0 cites
- 3683US2025340639A1Antibody constructs for dll3 and cd3AMGEN RES MUNICH GMBH·Filed 2025·Application pending·0 cites
- 3782US12297292B2Antibody constructs for CDH19 and CD3AMGEN INC·Filed 2017·Granted May 13, 2025·2 cites·12 claims
- 3882US10851170B2Antibody constructs for CD70 and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted Dec 1, 2020·3 cites·18 claims
- 3982US7435549B1Method of identifying binding site domains that retain the capacity of binding to an epitopeMICROMET AG·Filed 1998·Granted Oct 14, 2008·51 cites·47 claims
- 4082US7227002B1Human antibodies that bind human 17-A1/EpCAM tumor antigenMICROMET AG·Filed 1998·Granted Jun 5, 2007·52 cites·10 claims
- 4181US2022251243A1Binding molecules for bcma and cd3AMGEN INC·Filed 2022·Application pending·0 cites
- 4280US9695250B2Pharmaceutical compositions with resistance to soluble CEAAMGEN RES MUNICH GMBH·Filed 2013·Granted Jul 4, 2017·4 cites·19 claims
- 4379US11498964B2Antibody constructs for CDH19 and CD3AMGEN RES MUNICH GMBH·Filed 2018·Granted Nov 15, 2022·1 cites·17 claims
- 4478US12441796B2Antibody constructs for CDH19 and CD3AMGEN INC·Filed 2022·Granted Oct 14, 2025·0 cites·17 claims
- 4578US2025346684A1Binding molecules for bcma and cd3AMGEN INC·Filed 2025·Application pending·0 cites
- 4678US2024400673A1Antibody constructs for msln and cd3AMGEN RES MUNICH GMBH·Filed 2023·Application pending·0 cites
- 4777US8901278B2Pharmaceutical antibody compositions with resistance to soluble CEARAU DORIS·Filed 2011·Granted Dec 2, 2014·3 cites·2 claims
- 4876US12304952B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2021·Granted May 20, 2025·0 cites·16 claims
- 4976US12281175B2Binding molecules for BCMA and CD3AMGEN INC·Filed 2020·Granted Apr 22, 2025·0 cites·16 claims
- 5076US8247194B2Preparation of scFv antibody fragmentsRAUM TOBIAS·Filed 2005·Granted Aug 21, 2012·4 cites·15 claims
Showing the top 50 of 100 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →